Home

News

 

About the US initiative: Cancer Moonshot
HARMONY Interactive session at the 1st European Alliance for Personalised Medicine Congress.
Press Release | Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers
HARMONY Workshop on the definition of Outcomes
Valuable Interactions at the 2nd HARMONY General Assembly on 23 and 24 October in Berlin, Germany
Is the pharma industry missing the big picture? And can data-driven approaches reveal it? Sharing the new Elsevier Reaxys white paper.
Press Release HARMONY Alliance: Challenges and Opportunities for Using Big Data to Treat Hematologic Malignancies (HMs).
HARMONY Represented at the IMI Stakeholder Forum 2017
Meanwhile in the USA: a $215-million infusion to support immunotherapy work
Working together with patient groups. Sharing the EFPIA Patient Think Tank publication.
Data, data everywhere: the challenges of personalised medicine, new BJM article
Providers and payers share data to manage value-based care shift
2nd General Assembly HARMONY Alliance organized on 23 and 24 October in Berlin
The Pathway to Patient Data Ownership and Better Health
HARMONY Partner GMV explains HARMONY goals and objectives in largest Spanish newspaper.
Evidence for Health Decision Making beyond randomized, controlled trials.
The Patient Knows Best: Incorporating Patient-Reported Outcomes Into Routine Clinical Care
Big data analytics in healthcare comes with many challenges, including security, visualization, and a number of data integrity concerns.
HARMONY Partner Bambino Gesù Children’s Hospital presenting at the first conference on the innovation in pediatrics in Europe.
HARMONY Partner Novartis shares insight into the HARMONY Project and the road to improving patient outcomes across Europe
Informed consent models in the 21st century
The Innovative Medicines Initiative - carrying the torch for medical innovation.
HARMONY to present new bench-to-bedside projects during the 22nd Annual Congress of the European Hematology Association
Policies for Use of Real-World Data in Health Technology Assessment: A Comparative Study of Six HTA Agencies
1-24   25-48   49-72   73-96   97-120   121-144   145-168